11 names are moving together; 91% are participating in the current session.
Observed member paths adjusted against SPY. Shading marks the latest observation window.
| TICKER | Company | Sector | Today | Observed activity |
|---|---|---|---|---|
| MIRM | Mirum Pharmaceuticals, Inc. | Healthcare | -6.0% | 5/10 observed active sessions |
| PTGX | Protagonist Therapeutics, Inc. | Healthcare | -1.4% | 9/10 observed active sessions |
| VKTX | Viking Therapeutics, Inc. | Healthcare | -4.0% | 1/10 observed active sessions |
| PCVX | Vaxcyte, Inc. | Healthcare | -3.4% | 4/10 observed active sessions |
| SRRK | Scholar Rock Holding Corporatio | Healthcare | -3.4% | 1/10 observed active sessions |
| INSM | Insmed Incorporated | Healthcare | -2.8% | 3/10 observed active sessions |
| AXSM | Axsome Therapeutics, Inc. | Healthcare | -7.1% | 6/10 observed active sessions |
| APGE | Apogee Therapeutics, Inc. | Healthcare | -0.1% | 2/10 observed active sessions |
| IONS | Ionis Pharmaceuticals, Inc. | Healthcare | -2.8% | Group member |
| ARGX | argenx SE | Healthcare | -2.2% | Group member |
| ASND | Ascendis Pharma A/S | Healthcare | -2.9% | 1/10 observed active sessions |
Cohort
11 namesParticipation
91% this sessionObserved history
15 daily buildsThis identity theme becomes less useful if activity narrows to one or two names instead of remaining broad across the cohort.
MIRMcustomer · Not moving with the group now
Filing receipt · TAK / MIRM
“We expect that total product sales of our approved medicines will continue to increase on an annual basis; however, due to large periodic orders from Takeda and our dist…”
MIRM · customer
IONSpartner · Current intraday read unavailable
Filing receipt · NVS / IONS
“Our partner, Novartis, is responsible for ongoing development and commercialization of pelacarsen worldwide.”
IONS · partner
PCVXcustomer · Current intraday read unavailable
Filing receipt · STRO / PCVX
“Blackstone Relationship In June 2023, we entered into a purchase and sale agreement with Blackstone, or the Blackstone Agreement, to sell to Blackstone a revenue interes…”
PCVX · customer
PTGXcustomer · Moving with the group now · 115 min observed
Filing receipt · PFE / PTGX
“Pfizer, which completed its acquisition of Metsera in 2025, is developing next-generation oral and peptide-based incretin therapies for obesity and related cardiometabol…”
PTGX · customer
IONSpartner · Not moving with the group now
Filing receipt · BIIB / IONS
“Biogen Marketed Medicines SPINRAZA In 2012, we entered into a collaboration agreement with Biogen to develop and commercialize SPINRAZA.”
IONS · partner